Fox Run Management’s Kyntra Bio KYNB Stock Holding History

Fox Run Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,709	Closed	-$36.9K	–	818
2023 Q3	$36.9K	Buy	+1,709	New	+$67.1K	0.01%	662
2022 Q1	–	Sell	-655	Closed	-$231K	–	569
2021 Q4	$231K	Buy	+655	New	+$204K	0.14%	315
2020 Q1	–	Sell	-192	Closed	-$205K	–	199
2019 Q4	$205K	Buy	+192	New	+$196K	0.17%	321
2018 Q4	–	Sell	-320	Closed	-$486K	–	580
2018 Q3	$486K	Buy	+320	New	+$493K	0.21%	181
2018 Q2	–	Sell	-267	Closed	-$308K	–	748
2018 Q1	$308K	Buy	+267	New	+$352K	0.07%	484
2017 Q4	–	Sell	-700	Closed	-$942K	–	740
2017 Q3	$942K	Buy	+700	New	+$738K	0.27%	83
2017 Q2	–	Sell	-932	Closed	-$574K	–	691
2017 Q1	$574K	Buy	+932	New	+$568K	0.23%	139
2016 Q4	–	Sell	-492	Closed	-$255K	–	552
2016 Q3	$255K	Buy	492 +64	+15%	+$30.1K	0.15%	319
2016 Q2	$176K	Buy	+428	New	+$196K	0.09%	461

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fox Run Management's KYNB Position: Q4 2023 in Review

Fox Run Management sold out of Kyntra Bio (KYNB) in Q4 2023, closing a stake of 1,709 shares — an estimated $36.9K sold.

Fox Run Management first reported a position in KYNB in Q2 2016 and held it in 9 quarters. The position peaked at $942K in Q3 2017. 100 funds tracked by Wall St. Rank hold KYNB as of Q4 2023.

Fox Run Management reported no remaining Kyntra Bio position as of Q4 2023 after selling out during the quarter.
Fox Run Management sold 1,709 Kyntra Bio shares in Q4 2023, an estimated $36.9K.
Fox Run Management first reported a position in Kyntra Bio in Q2 2016 and held it in 9 quarters.
Fox Run Management's Kyntra Bio position peaked at $942K in Q3 2017.
100 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2023.

Based on Fox Run Management's 13F filing for Q4 2023, filed 13 Feb 2024.